알렌드로네이트의 생체이용률을 높이고 경구복용시 발생하는 부작용을 해소하고자 경피약물전달시스템에 전기이온영동법, microneedle 등을 적용하여 in-vitro 시험 후 약물전달량을 HPLC-Flu를 이용하여 조사하였다. 전기이온영동시험을 위해 사용된 약물 패취는 UV중합법으로 합성하였으며, 이때 패취에 함유된 알렌드로네이트의 량은 $5.0;mg/cm^3$이었다. 0.25, $0.50;mA/cm^2$의 전류를 인가한 경우, 약물전달량은 각각 $0.80{pm}0.03$와 $2.00{pm}0.02{mu}g$이었다. microneedle로 전처리 후의 전달량은 각각 $70.65{pm}0.37$와 $162.23{pm}0.40{mu}g$으로 증가했다. 경피약물전달용 알렌드로네이트 패취의 생체적 합성 평가는 ISO 10993에 따라 시험하였다.
This study examined the transdermal delivery of alendronate across hairless mouse skin. The effects of iontophoresis, perforation with a microneedle, and a combination of a microneedle pretreatment and iontophoresis were evaluated in vitro test. Hydrogel patches were polymerized by UN polymerization to supply a hydrogel patch to the iontophoretic transdermal drug delivery system. The alendronate content in the iontophoretic delivery patch was $5.0;mg/cm^3$. The amounts of alendronate that permeated across the hairless mouse skin when current densities of 0.25 and $0.50;mA/cm^2$ were supplied to the iontophoretic alendronate patch were $0.80{pm}0.03$ and $2.00{pm}0.02{mu}g$, respectively. After pretreatment with a microneedle, the amounts of alendronate that permeated across the hairless mouse skin increased to $70.65{pm}0.37$ and $162.23{pm}0.40{mu}g$, respectively. The biocompatibility of the iontophoretic alendronate patch was examined according to the international standardization organization 10993.
